Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

TSXV:HEM - Post Discussion

Hemostemix Inc > Reality check
View:
Post by Walterthedog on Sep 20, 2021 11:27am

Reality check

Now we're going to get institutional investment when no one is likely to buy the 25 cent public offering we have now? Who is going to invest in this dumpster fire when we have an unproven treatment that we may not even have the right to produce? The CEO say's the lawsuit is nonsense but there is a letter signed by Angus Jenkins stating that the late payment to Jed Wood would satisfy the condition precedent for the amended agreement giving Aspire the sole rights to ACP. I'm not a lawyer but that constitutes a big problem for anyone thinking of touching this. First it was January, then the end of February, then April then August, now "definitely this year." It's becoming clear that we can't get this phase 2 complete without data that Aspire is with holding. If that's the case, the company is finished. Aspire can likely drag out legal longer than we can and i'm pretty sure Peter Lacey can only float the costs for so long. Bottom line is either we can cobble together the phase 2 analysis without Aspire by years end as Smeenk claims or we're finished. And the way he dances around a concrete answer for the phase 2 completion, it really seems like more desperate stalling. I want to hope that we see a recovery and I'm waiting to see how this plays out but I fully expect to be diluted into oblivion before anything real happens with this company. Good luck fellas. We could really use some honesty from the company right now concerning how likely it is that we can complete the trial on our own but they will continue to paint you a nice picture until the truth can no longer be denied. And you guys can call me a basher all you like but the stock price should clue you in to what our chances really are here. FML what a disaster of an investment
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities